| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11458143 | SUPERNUS PHARMS | NA |
Sep, 2029
(5 years from now) | |
| US11324753 | SUPERNUS PHARMS | Method of treatment of attention deficit/hyperactivity disorder (ADHD) |
Sep, 2029
(5 years from now) | |
| US9358204 | SUPERNUS PHARMS | Formulations of viloxazine |
Feb, 2033
(9 years from now) | |
| US9603853 | SUPERNUS PHARMS | Formulations of viloxazine |
Feb, 2033
(9 years from now) | |
| US9662338 | SUPERNUS PHARMS | Formulations of viloxazine |
Feb, 2033
(9 years from now) | |
Qelbree is owned by Supernus Pharms.
Qelbree contains Viloxazine Hydrochloride.
Qelbree has a total of 5 drug patents out of which 0 drug patents have expired.
Qelbree was authorised for market use on 02 April, 2021.
Qelbree is available in capsule, extended release;oral dosage forms.
Qelbree can be used as u-727: for the treatment of attention deficit hyperactivity disorder (adhd), for the treatment of attention deficit hyperactivity disorder (adhd).
Drug patent challenges can be filed against Qelbree from 2025-04-02.
The generics of Qelbree are possible to be released after 07 February, 2033.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Apr 2, 2026 |
| New Patient Population (NPP) | Apr 29, 2025 |
Drugs and Companies using VILOXAZINE HYDROCHLORIDE ingredient
NCE-1 date: 2025-04-02
Market Authorisation Date: 02 April, 2021
Treatment: U-727: for the treatment of attention deficit hyperactivity disorder (adhd); For the treatment of attention deficit hyperactivity disorder (adhd)
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
QELBREE family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic